Developer docs
API playgroundTry for free, no card

Search company profiles

Immunexpress

Full company profile

uuid0006gls

Namestring
Immunexpress
Legal namestring
Immunexpress Inc.
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Immunexpress Inc. is a privately-held molecular diagnostics company headquartered in Seattle, USA, with R&D operations in Brisbane, Australia, focused on developing host-response-based clinical assays for the management of sepsis and immune disorders. The company's core product, SeptiCyte RAPID, is an FDA-cleared, CE-marked, and TGA-cleared PCR-based molecular diagnostic test that analyzes mRNA gene expression signatures from whole blood to differentiate non-infectious systemic inflammatory response syndrome (SIRS) from sepsis, producing a proprietary SeptiScore (0-15 across four probability bands) in approximately one hour. SeptiCyte RAPID runs exclusively on the Biocartis Idylla fully automated cartridge-based platform under a 2018 co-development and commercialization partnership, enabling low-hands-on-time deployment in hospital laboratories. The company also offers SeptiCyte LAB (a manual laboratory version) and has a pipeline product, SeptiCyte RAPID+, a second-generation nine-gene assay designed to additionally differentiate bacterial from viral sepsis in roughly 70 minutes.

The business model is anchored on cartridge/kit sales to hospital laboratories running on the Biocartis Idylla instrument, supplemented by platform equipment placement; pricing is quote-based and not publicly disclosed. Immunexpress pursues a sales-led, enterprise field sales go-to-market targeting hospital ICUs, emergency departments, and large healthcare systems, with adoption driven by peer-reviewed clinical validation studies, KOL endorsements, and multi-jurisdiction regulatory clearances (FDA, CE Mark, TGA pediatric). The company has raised approximately $67 million in disclosed equity funding from Debiopharm Group and Biocartis across 2012-2015 rounds, secured a $745K BARDA contract in 2019, and closed an undisclosed private round in October 2019. The customer base includes named collaborations with academic medical centers (Johns Hopkins, Emory, Brown, UCL, Amsterdam UMC) and US health systems (Intermountain, Providence, Cone Health, Northwell, Seattle Children's), with sepsis positioning addressing a market of 1.7 million annual US hospitalizations and over $41 billion in hospital costs.

Short descriptiontext

Immunexpress is a molecular diagnostics company developing FDA-cleared PCR-based host-response gene expression tests (SeptiCyte RAPID) for rapid (~1 hour) sepsis diagnosis, running on the Biocartis Idylla platform and serving hospital ICUs and emergency departments globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, sepsis diagnostics, host response testing, PCR diagnostic tests, clinical assay development
Industry2 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLACAGAF
Sepsis, Deterioration & Rapid Response CDS
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1SeptiCyte RAPID Test Kits
TypeOne Time License
Description

Sale of diagnostic test cartridges and consumables for use on the Biocartis Idylla platform. Hospitals purchase cartridges for each test performed.

immunexpress.com
2Idylla Platform Equipment
TypeHardware Sales
Description

Laboratory equipment sales or placement agreements with hospital laboratories for the Biocartis Idylla platform required to run SeptiCyte tests.

immunexpress.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
Pricing details1 tier
1Test pricing for hospital laboratory use
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based / Not publicly disclosed

immunexpress.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1SeptiCyte RAPID
Description

FDA-cleared, CE-marked rapid molecular diagnostic test for sepsis that delivers results in approximately one hour using the Biocartis Idylla platform

immunexpress.com
+2 more records
Core offering1 text field

Immunexpress develops and commercializes molecular diagnostic assays that analyze the host immune response from a whole blood sample to diagnose sepsis. Its flagship product, SeptiCyte RAPID, is a PCR-based cartridge test run on the Biocartis Idylla platform that delivers a SeptiScore (0–15) and differentiates sepsis from non-infectious SIRS in approximately one hour. Customers are hospital laboratories, ICUs, and emergency departments that need faster, more accurate sepsis triage than traditional 24–48 hour blood culture methods provide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Results delivered in ~1 hour vs 24-48 hours for traditional blood cultures
+5 more records
Product overview1 text field

Immunexpress offers a portfolio of molecular diagnostic products centered on SeptiCyte technology for sepsis detection. The core product, SeptiCyte RAPID, is a cartridge-based automated test running on the Biocartis Idylla platform that delivers results in approximately one hour by analyzing host immune response gene expression from whole blood. SeptiCyte LAB is the manual laboratory precursor that has been validated in extensive peer-reviewed clinical studies. The pipeline includes SeptiCyte RAPID+, a next-generation nine-gene expression assay designed to differentiate both sepsis from SIRS and bacterial from viral infections. All products leverage patented host immune response biomarkers and algorithms to provide objective sepsis probability scoring (SeptiScore).

Product and service2 records
1SeptiCyte RAPID
CategoryCore diagnostic product
Description

FDA-cleared, CE-marked, and TGA-cleared PCR-based molecular diagnostic cartridge that differentiates non-infectious systemic inflammatory response syndrome (SIRS) from sepsis in critically ill patients by analyzing host immune response gene expression signatures from whole blood. Delivers actionable results in approximately one hour on the Biocartis Idylla platform with a SeptiScore (0–15). For hospital laboratories, ICUs, and emergency departments.

2SeptiCyte LAB
CategoryCore diagnostic product
Description

Manual laboratory version of the host-response sepsis diagnostic test, validated in multiple peer-reviewed studies and originally developed prior to the automated SeptiCyte RAPID cartridge. For clinical and research laboratory use in discriminating sepsis from SIRS.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-04-01
Description

Extended sepsis assay development partnership with Novacyt. Novacyt is a molecular diagnostics company specializing in infectious disease testing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-02-01
Description

$745K HHS contract awarded through BARDA for continued development of SeptiCyte for rapid and accurate diagnosis of sepsis. BARDA is part of HHS focused on advanced research and development of medical countermeasures.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Partnership announced January 2018 to develop and commercialize a fully automated SeptiCyte LAB/RAPID test for use on Biocartis' Idylla platform. Idylla is a fully automated, RT-PCR based molecular testing system with compact scalable design. The partnership enables SeptiCyte tests to run on Idylla in hospital laboratory settings.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2013-04-01
Description

Collaboration to improve care of sepsis patients through the MARS (Molecule, Antibody, RNA Signature) consortium focused on sepsis research and diagnostics.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Non-profit organization dedicated to informing the public about sepsis dangers. Immunexpress partners with Sepsis Alliance on educational webinar programs focused on challenges of diagnosing sepsis. Collaboration supports awareness and clinical best-practices for early detection.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaborator presenting validation data on bacterial infection diagnosis and bacterial vs viral differentiation signatures.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaborator on studies discriminating sepsis from SIRS using SeptiCyte technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaborator on validation of host response assay for discriminating sepsis from SIRS in the ICU.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Healthcare system collaborator on sepsis diagnosis agreement studies and cartridge-based vs manual sepsis diagnosis testing.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Qiagen is a broad molecular diagnostics and sample-prep incumbent with sepsis-related PCR assay content and a deep hospital lab channel. Its board overlap (former Digene/Qiagen executives sit on Immunexpress's board) reflects the strategic adjacency in molecular Dx.

TypeOthers
Description

Biocartis is the platform partner for SeptiCyte RAPID via the Idylla system. While not a direct commercial competitor, Biocartis's commercial priorities and Idylla installed-base trajectory directly determine Immunexpress's route to market and cartridge-volume opportunity.

TypeDirect peer
Description

T2 Biosystems markets T2Bacteria and T2Candida direct-from-blood molecular diagnostic panels for sepsis-causing pathogens, targeting the same ICU/critical care customer segment with rapid, cartridge-based testing — competing for hospital lab budgets and clinical workflow mindshare.

TypeDirect peer
Description

Inflammatix is developing host-response-based molecular diagnostics for acute infection and sepsis, targeting similar clinical use cases (rapid differentiation of infection vs inflammation) with a different biomarker signature — a direct competitor for clinical adoption and hospital lab accounts.

TypeDirect peer
Description

Cytovale commercializes IntelliSep, an FDA-cleared rapid host-response sepsis diagnostic that runs on a different platform but competes directly with SeptiCyte RAPID for the same ICU/ED use case and customer (hospital labs). It is the most direct functional competitor in the rapid host-response sepsis Dx category.

TypeBroad incumbent
Description

Cepheid's GeneXpert is the most widely deployed rapid PCR platform in hospital labs, including for bloodstream infection/sepsis-related applications. It is the primary incumbent rapid molecular testing platform that Immunexpress must position against for ICU/ED workflows.

TypeEmerging player
Description

Prenosis developed Sepsis ImmunoScore, an FDA-cleared AI-driven host-response diagnostic for sepsis risk, overlapping with Immunexpress on the host-response approach and sepsis decision support category, though using immunoassay rather than PCR.

TypeBroad incumbent
Description

bioMérieux is the incumbent leader in clinical microbiology and sepsis-related diagnostics (blood culture, procalcitonin / BIOFIRE products) — the dominant workflow Immunexpress must displace in hospital labs, with extensive commercial reach and reimbursement infrastructure.

TypeBroad incumbent
Description

Roche operates broad molecular diagnostics, immunoassays (procalcitonin / Elecsys BRAHMS PCT), and central lab platforms used in sepsis workups. As a large incumbent, it competes for hospital lab sepsis testing budgets across multiple assay formats.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott offers molecular diagnostics platforms (e.g., m2000, Alinity m) and immunoassays used in sepsis evaluation, and is one of the larger IVD competitors for the hospital lab customer that Immunexpress targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immunexpress

Molecular Diagnosticsimmunexpress.com

Immunexpress is a molecular diagnostics company developing FDA-cleared PCR-based host-response gene expression tests (SeptiCyte RAPID) for rapid (~1 hour) sepsis diagnosis, running on the Biocartis Idylla platform and serving hospital ICUs and emergency departments globally.

What Immunexpress does

Immunexpress Inc. is a privately-held molecular diagnostics company headquartered in Seattle, USA, with R&D operations in Brisbane, Australia, focused on developing host-response-based clinical assays for the management of sepsis and immune disorders. The company's core product, SeptiCyte RAPID, is an FDA-cleared, CE-marked, and TGA-cleared PCR-based molecular diagnostic test that analyzes mRNA gene expression signatures from whole blood to differentiate non-infectious systemic inflammatory response syndrome (SIRS) from sepsis, producing a proprietary SeptiScore (0-15 across four probability bands) in approximately one hour. SeptiCyte RAPID runs exclusively on the Biocartis Idylla fully automated cartridge-based platform under a 2018 co-development and commercialization partnership, enabling low-hands-on-time deployment in hospital laboratories. The company also offers SeptiCyte LAB (a manual laboratory version) and has a pipeline product, SeptiCyte RAPID+, a second-generation nine-gene assay designed to additionally differentiate bacterial from viral sepsis in roughly 70 minutes.

The business model is anchored on cartridge/kit sales to hospital laboratories running on the Biocartis Idylla instrument, supplemented by platform equipment placement; pricing is quote-based and not publicly disclosed. Immunexpress pursues a sales-led, enterprise field sales go-to-market targeting hospital ICUs, emergency departments, and large healthcare systems, with adoption driven by peer-reviewed clinical validation studies, KOL endorsements, and multi-jurisdiction regulatory clearances (FDA, CE Mark, TGA pediatric). The company has raised approximately $67 million in disclosed equity funding from Debiopharm Group and Biocartis across 2012-2015 rounds, secured a $745K BARDA contract in 2019, and closed an undisclosed private round in October 2019. The customer base includes named collaborations with academic medical centers (Johns Hopkins, Emory, Brown, UCL, Amsterdam UMC) and US health systems (Intermountain, Providence, Cone Health, Northwell, Seattle Children's), with sepsis positioning addressing a market of 1.7 million annual US hospitalizations and over $41 billion in hospital costs.

Immunexpress firmographics

Firmographics
Name
Immunexpress
Legal name
Immunexpress Inc.
Website
https://immunexpress.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Immunexpress is a molecular diagnostics company developing FDA-cleared PCR-based host-response gene expression tests (SeptiCyte RAPID) for rapid (~1 hour) sepsis diagnosis, running on the Biocartis Idylla platform and serving hospital ICUs and emergency departments globally.
Ownership category
akta.pro rank

Immunexpress industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLACAGAF
Sepsis, Deterioration & Rapid Response CDS
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Molecular diagnostics
  • Sepsis diagnostics
  • Host response testing
  • PCR diagnostic tests
  • Clinical assay development

Where Immunexpress is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Immunexpress business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. SeptiCyte RAPID Test Kits: Sale of diagnostic test cartridges and consumables for use on the Biocartis Idylla platform. Hospitals purchase cartridges for each test performed.
  2. Idylla Platform Equipment: Laboratory equipment sales or placement agreements with hospital laboratories for the Biocartis Idylla platform required to run SeptiCyte tests.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goTest pricing for hospital laboratory use

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Immunexpress product offering

Product offering

Core offering

Immunexpress develops and commercializes molecular diagnostic assays that analyze the host immune response from a whole blood sample to diagnose sepsis. Its flagship product, SeptiCyte RAPID, is a PCR-based cartridge test run on the Biocartis Idylla platform that delivers a SeptiScore (0–15) and differentiates sepsis from non-infectious SIRS in approximately one hour. Customers are hospital laboratories, ICUs, and emergency departments that need faster, more accurate sepsis triage than traditional 24–48 hour blood culture methods provide.

Product overview

Immunexpress offers a portfolio of molecular diagnostic products centered on SeptiCyte technology for sepsis detection. The core product, SeptiCyte RAPID, is a cartridge-based automated test running on the Biocartis Idylla platform that delivers results in approximately one hour by analyzing host immune response gene expression from whole blood. SeptiCyte LAB is the manual laboratory precursor that has been validated in extensive peer-reviewed clinical studies. The pipeline includes SeptiCyte RAPID+, a next-generation nine-gene expression assay designed to differentiate both sepsis from SIRS and bacterial from viral infections. All products leverage patented host immune response biomarkers and algorithms to provide objective sepsis probability scoring (SeptiScore).

Differentiator

Problem solved

Functional benefit

Brands

  • SeptiCyte RAPID: FDA-cleared, CE-marked rapid molecular diagnostic test for sepsis that delivers results in approximately one hour using the Biocartis Idylla platform
  • SeptiCyte LAB
  • SeptiCyte RAPID+

Products and services

  • SeptiCyte RAPID FDA-cleared, CE-marked, and TGA-cleared PCR-based molecular diagnostic cartridge that differentiates non-infectious systemic inflammatory response syndrome (SIRS) from sepsis in critically ill patients by analyzing host immune response gene expression signatures from whole blood. Delivers actionable results in approximately one hour on the Biocartis Idylla platform with a SeptiScore (0–15). For hospital laboratories, ICUs, and emergency departments.
  • SeptiCyte LAB Manual laboratory version of the host-response sepsis diagnostic test, validated in multiple peer-reviewed studies and originally developed prior to the automated SeptiCyte RAPID cartridge. For clinical and research laboratory use in discriminating sepsis from SIRS.

Quantifiable outcome

  • Results delivered in ~1 hour vs 24-48 hours for traditional blood cultures
  • +5 more outcomes

Companies that use Immunexpress

Customer profile

Named customers12 records

Segments6 records

Ideal customer profiles2 records

Immunexpress technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature5 records

Immunexpress partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • NovacytminorStrategic or Co-development Partner · 1 April 2019Extended sepsis assay development partnership with Novacyt. Novacyt is a molecular diagnostics company specializing in infectious disease testing.
  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 1 February 2019$745K HHS contract awarded through BARDA for continued development of SeptiCyte for rapid and accurate diagnosis of sepsis. BARDA is part of HHS focused on advanced research and development of medical countermeasures.
  • BiocartiscoreStrategic or Co-development Partner · 1 January 2018Partnership announced January 2018 to develop and commercialize a fully automated SeptiCyte LAB/RAPID test for use on Biocartis' Idylla platform. Idylla is a fully automated, RT-PCR based molecular testing system with compact scalable design. The partnership enables SeptiCyte tests to run on Idylla in hospital laboratory settings.
  • MARS ConsortiumminorStrategic or Co-development Partner · 1 April 2013Collaboration to improve care of sepsis patients through the MARS (Molecule, Antibody, RNA Signature) consortium focused on sepsis research and diagnostics.
  • Sepsis AlliancecoreGTM or Marketing PartnerNon-profit organization dedicated to informing the public about sepsis dangers. Immunexpress partners with Sepsis Alliance on educational webinar programs focused on challenges of diagnosing sepsis. Collaboration supports awareness and clinical best-practices for early detection.
  • UCL (University College London)minorStrategic or Co-development PartnerAcademic collaborator presenting validation data on bacterial infection diagnosis and bacterial vs viral differentiation signatures.
  • Amsterdam UMCminorStrategic or Co-development PartnerAcademic collaborator on studies discriminating sepsis from SIRS using SeptiCyte technology.
  • Brown UniversityminorStrategic or Co-development PartnerAcademic collaborator on validation of host response assay for discriminating sepsis from SIRS in the ICU.
  • Intermountain HealthminorStrategic or Co-development PartnerHealthcare system collaborator on sepsis diagnosis agreement studies and cartridge-based vs manual sepsis diagnosis testing.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Immunexpress competitors and assessment

Company assessment

Broad incumbents

  • Qiagen: Qiagen is a broad molecular diagnostics and sample-prep incumbent with sepsis-related PCR assay content and a deep hospital lab channel. Its board overlap (former Digene/Qiagen executives sit on Immunexpress's board) reflects the strategic adjacency in molecular Dx.
  • Cepheid (Danaher): Cepheid's GeneXpert is the most widely deployed rapid PCR platform in hospital labs, including for bloodstream infection/sepsis-related applications. It is the primary incumbent rapid molecular testing platform that Immunexpress must position against for ICU/ED workflows.
  • bioMérieux: bioMérieux is the incumbent leader in clinical microbiology and sepsis-related diagnostics (blood culture, procalcitonin / BIOFIRE products) — the dominant workflow Immunexpress must displace in hospital labs, with extensive commercial reach and reimbursement infrastructure.
  • Roche Diagnostics: Roche operates broad molecular diagnostics, immunoassays (procalcitonin / Elecsys BRAHMS PCT), and central lab platforms used in sepsis workups. As a large incumbent, it competes for hospital lab sepsis testing budgets across multiple assay formats.
  • Abbott Diagnostics: Abbott offers molecular diagnostics platforms (e.g., m2000, Alinity m) and immunoassays used in sepsis evaluation, and is one of the larger IVD competitors for the hospital lab customer that Immunexpress targets.

Others

  • Biocartis: Biocartis is the platform partner for SeptiCyte RAPID via the Idylla system. While not a direct commercial competitor, Biocartis's commercial priorities and Idylla installed-base trajectory directly determine Immunexpress's route to market and cartridge-volume opportunity.

Direct peers

  • T2 Biosystems: T2 Biosystems markets T2Bacteria and T2Candida direct-from-blood molecular diagnostic panels for sepsis-causing pathogens, targeting the same ICU/critical care customer segment with rapid, cartridge-based testing — competing for hospital lab budgets and clinical workflow mindshare.
  • Inflammatix: Inflammatix is developing host-response-based molecular diagnostics for acute infection and sepsis, targeting similar clinical use cases (rapid differentiation of infection vs inflammation) with a different biomarker signature — a direct competitor for clinical adoption and hospital lab accounts.
  • Cytovale: Cytovale commercializes IntelliSep, an FDA-cleared rapid host-response sepsis diagnostic that runs on a different platform but competes directly with SeptiCyte RAPID for the same ICU/ED use case and customer (hospital labs). It is the most direct functional competitor in the rapid host-response sepsis Dx category.

Emerging players

  • Prenosis: Prenosis developed Sepsis ImmunoScore, an FDA-cleared AI-driven host-response diagnostic for sepsis risk, overlapping with Immunexpress on the host-response approach and sepsis decision support category, though using immunoassay rather than PCR.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Immunexpress social profiles

Digital presence

Immunexpress compliance and trust

Trust signal

Compliance4 records

Immunexpress financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immunexpress leadership team

Management profile

Number of profiles

Profiles16 records

Immunexpress funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immunexpress M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunexpress

What does Immunexpress do?

Immunexpress develops and commercializes molecular diagnostic assays that analyze the host immune response from a whole blood sample to diagnose sepsis. Its flagship product, SeptiCyte RAPID, is a PCR-based cartridge test run on the Biocartis Idylla platform that delivers a SeptiScore (0–15) and differentiates sepsis from non-infectious SIRS in approximately one hour. Customers are hospital laboratories, ICUs, and emergency departments that need faster, more accurate sepsis triage than traditional 24–48 hour blood culture methods provide.

Is Immunexpress a public or private company?

Immunexpress is a private company. It is classified as venture growth investor backed and is currently operating.

When was Immunexpress founded?

Immunexpress was founded in 2006. It employs 11 to 50 people.

Where is Immunexpress based?

Immunexpress is headquartered in Seattle, United States, in the North America region.

How does Immunexpress make money?

Two revenue lines are on record. SeptiCyte RAPID Test Kits are the primary driver. The others are idylla Platform Equipment.

Who are Immunexpress's main competitors?

Broad incumbents on record are Qiagen, Cepheid (Danaher), bioMérieux, Roche Diagnostics and Abbott Diagnostics. Biocartis is listed as an others. Direct peers are T2 Biosystems, Inflammatix and Cytovale. Prenosis is listed as an emerging player.

Does Immunexpress have an API?

No public API is recorded for Immunexpress.

What industry is Immunexpress in?

Immunexpress's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLACAGAF, Sepsis, Deterioration & Rapid Response CDS. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireNew Publication Supports the Role of SeptiCyte® RAPID To Improve Infection Diagnosis in Post Surgery and Trauma PatientsA study published in BMC Anesthesiology evaluated SeptiCyte RAPID for distinguishing healthcare-associated infections from sterile inflammation in critically ill trauma patients. The test showed 100% sensitivity, 90% specificity, and an AUC of 0.98 in validation, with results in one hour. The findings suggest it may enable earlier diagnosis and reduce unnecessary antibiotic exposure.PR NewswireImmunexpress Presenting at the Society of Critical Care Medicine (SCCM) 2026 Critical Care Congress Showing SeptiCyte RAPID® High Correlation with Blood Culture Positive Sepsis PatientsImmunexpress announced its participation at the SCCM 2026 Critical Care Congress in Chicago from March 22-24, 2026, where the company will present data demonstrating SeptiCyte RAPID's high correlation with blood culture positive sepsis patients. Chief Medical Officer Dr. Roy Davis will present an abstract titled 'Determining the Likelihood of Blood Culture Positivity in Sepsis in One Hour Using SeptiCyte RAPID' as part of the Research Snapshot Theatre. SeptiCyte RAPID is FDA-cleared in the United States and CE Marked in Europe, running on the Biocartis Idylla platform to deliver sepsis risk assessment results within approximately one hour.PR NewswireImmunexpress Announces Publication Demonstrating SeptiCyte RAPID® Utility for Differentiating Infection from Sterile Inflammation in Readmitted Bone Marrow Transplant Patients with Febrile NeutropaeniImmunexpress announced publication of a study in the European Journal of Haematology demonstrating that SeptiCyte RAPID® can differentiate non-infectious inflammation from severe infection in febrile neutropenia patients with hematological malignancies after bone marrow stem cell transplantation. The study showed strong diagnostic performance with an AUC of 0.84 and an optimal SeptiScore cut point of 6.9, with performance preserved across different malignancy subgroups including patients with extremely low leukocyte counts. Associate Professor Patrick Harris noted the test may support earlier differentiation to help guide antimicrobial decisions and stewardship in patients where conventional microbiology is often negative or slow.PR NewswireImmunexpress Announces Publication Showing SeptiCyte RAPID® Identifies Septic Patients Most Likely to Have Positive Blood CulturesImmunexpress announced publication of a multi-center study demonstrating that elevated SeptiCyte RAPID scores are strongly associated with blood culture positivity in sepsis patients, with the retrospective analysis covering 506 critically ill patients across North America, Europe, and sub-Saharan Africa. The study showed strong diagnostic performance with an AUC of 0.91, achieving 100% sensitivity at low SeptiScores and 100% specificity at high SeptiScores, suggesting the test can help clinicians prioritize patients most likely to benefit from blood cultures and reduce unnecessary testing.PR Newswire2 New Published Studies Highlight SeptiCyte RAPID's Strong Performance and Clinical Utility in Post Cardiac Surgery PatientsImmunexpress announced the publication of two peer-reviewed studies demonstrating SeptiCyte RAPID's diagnostic accuracy in differentiating sepsis from non-infectious systemic inflammation in high-risk post-cardiac surgery patients, published in the International Journal of Molecular Sciences and Journal of Critical Care. The first study at Turin, Italy showed elevated SeptiScore correlated with greater clinical severity in infective endocarditis patients, while the second at Nancy, France demonstrated a 100% negative predictive value and AUC of 0.93 for detecting peritonitis, significantly outperforming conventional biomarkers. These findings support the test's clinical utility for sepsis diagnosis and antibiotic stewardship in critical care settings.PR NewswireStudy Published in the Journal Infection Demonstrates Clinical Utility of SeptiCyte® RAPID to Diagnose Sepsis in Critically Ill Patients with Hospital Acquired InfectionsImmunexpress announced publication of a clinical validation study in the journal Infection demonstrating that its SeptiCyte RAPID molecular diagnostic test significantly outperformed traditional biomarkers procalcitonin and C-reactive protein in distinguishing sepsis from systemic inflammatory response syndrome in critically ill ICU patients with nosocomial infections. The prospective observational study enrolled 69 patients and found SeptiCyte RAPID achieved an AUC of 0.995 compared to 0.600 for procalcitonin and 0.703 for C-reactive protein, with 91.4% sensitivity and 73.5% specificity. The company suggests the test could support antibiotic stewardship by helping reduce unnecessary antimicrobial use in hospitalized patients.Pulse 2.0Immunexpress: Creating Molecular Diagnostics For Sepsis In A $1 Billion MarketImmunexpress CEO Rollie Carlson discussed the company's SeptiCyte RAPID sepsis test, a gene expression-based diagnostic cleared by the FDA, EU, and Australia. The test measures immune response to differentiate sepsis from systemic inflammation, and the company targets a $1 billion sepsis diagnostics market. Future goals include expanding adoption and testing in immunocompromised patients.PR NewswireCHEST 2023 Poster Demonstrates the Utility of SeptiCyte® RAPID in Antibiotic Administration and Sepsis Bundle ComplianceImmunexpress announced a poster presentation at CHEST 2023 demonstrating the utility of its SeptiCyte® RAPID test in aiding antibiotic administration and improving sepsis bundle compliance. A retrospective study of 62 patients indicated that the test's SeptiScore correlated with clinical assessments, potentially facilitating discrimination of intermediate probability sepsis cases.PR NewswireImmunexpress to Present Data at ISICEM 2023 Indicating that SeptiCyte® RAPID Outperforms Other Rapid Measures for Sepsis DiagnosisImmunexpress announced at ISICEM 2023 that its SeptiCyte RAPID molecular diagnostic test outperformed conventional rapid sepsis diagnosis methods, including qSOFA, lactate, PCT, and SOFA scores, in a study of 419 critically ill ICU patients suspected of sepsis. The test achieved AUC scores of 0.82 and 0.81 regardless of qSOFA stratification and demonstrated utility as an early step in the sepsis diagnostic pathway under the Sepsis-3 framework. SeptiCyte RAPID is CE Marked in the EU and FDA cleared as of November 2021, and runs on Biocartis' Idylla Platform under a commercialization partnership.